| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| XERS - Xeris Pharmaceuticals Inc | BUY | 274 @ USD 7.43 | USD 2,036 | The ETF bought 274 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.43 compared to the previous average buy price of 6.04632. This is 22.9% higher than average price of previous purchases of XERS. |
| URGN - UroGen Pharma Ltd | BUY | 79 @ USD 23.24 | USD 1,836 | The ETF bought 79 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 23.24 compared to the previous average buy price of 14.4605. This is 60.7% higher than average price of previous purchases of URGN. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 592 @ USD 2.3 | USD 1,362 | The ETF bought 592 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.3 compared to the previous average buy price of 2.43712. This is -5.6% lower than average price of previous purchases of IOVA. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.91 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.91. The average price that ABCL shares were previous bought at was USD 3.90978. The current market price is 0.0% higher than average price they were purchased at. The value of the holding in ABCL has fallen by USD 118,675 compared to the previous valuation of Abcellera Biologics Inc |
| ABUS - Arbutus Biopharma Corp | HOLD | 0 @ USD 4.5 | USD 0 | The current share valuation price of ABUS based on adjusted close was USD 4.5. The average price that ABUS shares were previous bought at was USD 3.62433. The current market price is 24.2% higher than average price they were purchased at. The value of the holding in ABUS has increased by USD 7,504 compared to the previous valuation of Arbutus Biopharma Corp however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 22.57 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 22.57. The average price that ACAD shares were previous bought at was USD 20.7824. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in ACAD has increased by USD 100,922 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ACIU - AC Immune Ltd | HOLD | 0 @ USD 3.3 | USD 0 | The current share valuation price of ACIU based on adjusted close was USD 3.3. The average price that ACIU shares were previous bought at was USD 2.38505. The current market price is 38.4% higher than average price they were purchased at. The value of the holding in ACIU has fallen by USD 9,606 compared to the previous valuation of AC Immune Ltd |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 86.55 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 86.55. The average price that ACLX shares were previous bought at was USD 71.6817. The current market price is 20.7% higher than average price they were purchased at. The value of the holding in ACLX has fallen by USD 59,180 compared to the previous valuation of Arcellx Inc |
| ADMA - ADMA Biologics Inc | HOLD | 0 @ USD 14.52 | USD 0 | The current share valuation price of ADMA based on adjusted close was USD 14.52. The average price that ADMA shares were previous bought at was USD 17.3935. The current market price is -16.5% lower than average price they were purchased at. The value of the holding in ADMA has increased by USD 76,021 compared to the previous valuation of ADMA Biologics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 14.79 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 14.79. The average price that ADPT shares were previous bought at was USD 11.841. The current market price is 24.9% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 75,053 compared to the previous valuation of Adaptive Biotechnologies Corp |
| AGIO - Agios Pharm | HOLD | 0 @ USD 40.67 | USD 0 | The current share valuation price of AGIO based on adjusted close was USD 40.67. The average price that AGIO shares were previous bought at was USD 35.7468. The current market price is 13.8% higher than average price they were purchased at. The value of the holding in AGIO has increased by USD 13,385 compared to the previous valuation of Agios Pharm however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| AKRO - Akero Therapeutics Inc | HOLD | 0 @ USD 54.04 | USD 0 | The current share valuation price of AKRO based on adjusted close was USD 54.04. The average price that AKRO shares were previous bought at was USD 49.2183. The current market price is 9.8% higher than average price they were purchased at. The value of the holding in AKRO has increased by USD 6,740 compared to the previous valuation of Akero Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ALEC - Alector Inc | HOLD | 0 @ USD 1.28 | USD 0 | The current share valuation price of ALEC based on adjusted close was USD 1.28. The average price that ALEC shares were previous bought at was USD 1.95849. The current market price is -34.6% lower than average price they were purchased at. The value of the holding in ALEC has fallen by USD 1,363 compared to the previous valuation of Alector Inc |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 32.89 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 32.89. The average price that ALKS shares were previous bought at was USD 30.4206. The current market price is 8.1% higher than average price they were purchased at. The value of the holding in ALKS has increased by USD 129,165 compared to the previous valuation of Alkermes Plc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.18 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.18. The average price that ALLO shares were previous bought at was USD 1.33815. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in ALLO has increased by USD 18,259 compared to the previous valuation of Allogene Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 442.7 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 442.7. The average price that ALNY shares were previous bought at was USD 356.611. The current market price is 24.1% higher than average price they were purchased at. The value of the holding in ALNY has increased by USD 185,718 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ALT - Altitude Group Plc | HOLD | 0 @ USD 4.10999 | USD 0 | The current share valuation price of ALT based on adjusted close was USD 4.10999. The average price that ALT shares were previous bought at was USD 5.27691. The current market price is -22.1% lower than average price they were purchased at. The value of the holding in ALT has increased by USD 9,271 compared to the previous valuation of Altitude Group Plc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 320.2 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 320.2. The average price that AMGN shares were previous bought at was USD 288.162. The current market price is 11.1% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 857,152 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 12.31 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 12.31. The average price that AMLX shares were previous bought at was USD 6.86127. The current market price is 79.4% higher than average price they were purchased at. The value of the holding in AMLX has fallen by USD 8,567 compared to the previous valuation of Amylyx Pharmaceuticals Inc |
| AMPH - Amphastar P | HOLD | 0 @ USD 24.03 | USD 0 | The current share valuation price of AMPH based on adjusted close was USD 24.03. The average price that AMPH shares were previous bought at was USD 25.5803. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in AMPH has fallen by USD 5,953 compared to the previous valuation of Amphastar P |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | HOLD | 0 @ USD 11.37 | USD 0 | The current share valuation price of AMRX based on adjusted close was USD 11.37. The average price that AMRX shares were previous bought at was USD 8.75668. The current market price is 29.8% higher than average price they were purchased at. The value of the holding in AMRX has fallen by USD 59,307 compared to the previous valuation of Amneal Pharmaceuticals, Inc. Class A Common Stock |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 39.65 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 39.65. The average price that ANAB shares were previous bought at was USD 23.8479. The current market price is 66.3% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 25,999 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ANIP - ANI Pharmaceuticals Inc | HOLD | 0 @ USD 90.43 | USD 0 | The current share valuation price of ANIP based on adjusted close was USD 90.43. The average price that ANIP shares were previous bought at was USD 72.4067. The current market price is 24.9% higher than average price they were purchased at. The value of the holding in ANIP has increased by USD 2,779 compared to the previous valuation of ANI Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| APGE - Apogee Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 54.71 | USD 0 | The current share valuation price of APGE based on adjusted close was USD 54.71. The average price that APGE shares were previous bought at was USD 43.5168. The current market price is 25.7% higher than average price they were purchased at. The value of the holding in APGE has fallen by USD 8,409 compared to the previous valuation of Apogee Therapeutics, Inc. Common Stock |
| APLS - Apellis Pharmaceuticals Inc | HOLD | 0 @ USD 19.26 | USD 0 | The current share valuation price of APLS based on adjusted close was USD 19.26. The average price that APLS shares were previous bought at was USD 21.1104. The current market price is -8.8% lower than average price they were purchased at. The value of the holding in APLS has fallen by USD 36,998 compared to the previous valuation of Apellis Pharmaceuticals Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 8.72001 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 8.72001. The average price that ARCT shares were previous bought at was USD 14.828. The current market price is -41.2% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 7,860 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ARDX - Ardelyx Inc | HOLD | 0 @ USD 5.59 | USD 0 | The current share valuation price of ARDX based on adjusted close was USD 5.59. The average price that ARDX shares were previous bought at was USD 4.59538. The current market price is 21.6% higher than average price they were purchased at. The value of the holding in ARDX has fallen by USD 9,263 compared to the previous valuation of Ardelyx Inc |
| ARGX - argenx NV ADR | HOLD | 0 @ USD 854.65 | USD 0 | The current share valuation price of ARGX based on adjusted close was USD 854.65. The average price that ARGX shares were previous bought at was USD 634.553. The current market price is 34.7% higher than average price they were purchased at. The value of the holding in ARGX has increased by USD 71,955 compared to the previous valuation of argenx NV ADR however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ARQT - Arcutis Biotherapeutics Inc | HOLD | 0 @ USD 24.23 | USD 0 | The current share valuation price of ARQT based on adjusted close was USD 24.23. The average price that ARQT shares were previous bought at was USD 16.0714. The current market price is 50.8% higher than average price they were purchased at. The value of the holding in ARQT has fallen by USD 66,772 compared to the previous valuation of Arcutis Biotherapeutics Inc |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 10.63 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 10.63. The average price that ARVN shares were previous bought at was USD 8.7263. The current market price is 21.8% higher than average price they were purchased at. The value of the holding in ARVN has increased by USD 28,946 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ARWR - Arrowhead Pharmaceuticals Inc | HOLD | 0 @ USD 39.23 | USD 0 | The current share valuation price of ARWR based on adjusted close was USD 39.23. The average price that ARWR shares were previous bought at was USD 20.9353. The current market price is 87.4% higher than average price they were purchased at. The value of the holding in ARWR has fallen by USD 33,094 compared to the previous valuation of Arrowhead Pharmaceuticals Inc |
| ASND - Ascendis Pharma AS | HOLD | 0 @ USD 197.74 | USD 0 | The current share valuation price of ASND based on adjusted close was USD 197.74. The average price that ASND shares were previous bought at was USD 177.391. The current market price is 11.5% higher than average price they were purchased at. The value of the holding in ASND has fallen by USD 60,449 compared to the previous valuation of Ascendis Pharma AS |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 14.61 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 14.61. The average price that AUPH shares were previous bought at was USD 9.03759. The current market price is 61.7% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 55,643 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| AUTL - Autolus Therapeutics Ltd | HOLD | 0 @ USD 1.33 | USD 0 | The current share valuation price of AUTL based on adjusted close was USD 1.33. The average price that AUTL shares were previous bought at was USD 1.84388. The current market price is -27.9% lower than average price they were purchased at. The value of the holding in AUTL has fallen by USD 4,180 compared to the previous valuation of Autolus Therapeutics Ltd |
| AVDL - Avadel Pharmaceuticals PLC | HOLD | 0 @ USD 18.69 | USD 0 | The current share valuation price of AVDL based on adjusted close was USD 18.69. The average price that AVDL shares were previous bought at was USD 10.7616. The current market price is 73.7% higher than average price they were purchased at. The value of the holding in AVDL has fallen by USD 1,244 compared to the previous valuation of Avadel Pharmaceuticals PLC |
| AVIR - Atea Pharmaceuticals Inc | HOLD | 0 @ USD 3.27 | USD 0 | The current share valuation price of AVIR based on adjusted close was USD 3.27. The average price that AVIR shares were previous bought at was USD 3.32765. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in AVIR has increased by USD 1,075 compared to the previous valuation of Atea Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| AVXL - Anavex Life Sciences Corp | HOLD | 0 @ USD 7.29 | USD 0 | The current share valuation price of AVXL based on adjusted close was USD 7.29. The average price that AVXL shares were previous bought at was USD 9.55786. The current market price is -23.7% lower than average price they were purchased at. The value of the holding in AVXL has fallen by USD 6,057 compared to the previous valuation of Anavex Life Sciences Corp |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 138.15 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 138.15. The average price that AXSM shares were previous bought at was USD 114.398. The current market price is 20.8% higher than average price they were purchased at. The value of the holding in AXSM has fallen by USD 40,575 compared to the previous valuation of Axsome Therapeutics Inc |
| AZN - AstraZeneca PLC | HOLD | 0 @ USD 84.58 | USD 0 | The current share valuation price of AZN based on adjusted close was USD 84.58. The average price that AZN shares were previous bought at was USD 74.4108. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in AZN has increased by USD 271,159 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| BBIO - BridgeBio Pharma Inc | HOLD | 0 @ USD 61.8 | USD 0 | The current share valuation price of BBIO based on adjusted close was USD 61.8. The average price that BBIO shares were previous bought at was USD 44.1594. The current market price is 39.9% higher than average price they were purchased at. The value of the holding in BBIO has fallen by USD 115,210 compared to the previous valuation of BridgeBio Pharma Inc |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.09 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.09. The average price that BCRX shares were previous bought at was USD 8.3353. The current market price is -14.9% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 8,067 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| BCYC - Bicycle Therapeutics Ltd | HOLD | 0 @ USD 6.43999 | USD 0 | The current share valuation price of BCYC based on adjusted close was USD 6.43999. The average price that BCYC shares were previous bought at was USD 8.60328. The current market price is -25.1% lower than average price they were purchased at. The value of the holding in BCYC has fallen by USD 2,127 compared to the previous valuation of Bicycle Therapeutics Ltd |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 22.21 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 22.21. The average price that BEAM shares were previous bought at was USD 20.557. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in BEAM has fallen by USD 60,856 compared to the previous valuation of Beam Therapeutics Inc |
| BIIB - Biogen Inc | HOLD | 0 @ USD 155.51 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 155.51. The average price that BIIB shares were previous bought at was USD 137.903. The current market price is 12.8% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 116,610 compared to the previous valuation of Biogen Inc |
| BMEA - Biomea Fusion Inc | HOLD | 0 @ USD 1.37001 | USD 0 | The current share valuation price of BMEA based on adjusted close was USD 1.37001. The average price that BMEA shares were previous bought at was USD 1.82675. The current market price is -25.0% lower than average price they were purchased at. The value of the holding in BMEA has increased by USD 3,112 compared to the previous valuation of Biomea Fusion Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 51.46 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 51.46. The average price that BMRN shares were previous bought at was USD 58.3018. The current market price is -11.7% lower than average price they were purchased at. The value of the holding in BMRN has fallen by USD 47,056 compared to the previous valuation of Biomarin Pharmaceutical Inc |
| BNTX - BioNTech SE | HOLD | 0 @ USD 103.14 | USD 0 | The current share valuation price of BNTX based on adjusted close was USD 103.14. The average price that BNTX shares were previous bought at was USD 105.061. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in BNTX has fallen by USD 13,625 compared to the previous valuation of BioNTech SE |
| CGEM - Cullinan Oncology LLC | HOLD | 0 @ USD 7.18999 | USD 0 | The current share valuation price of CGEM based on adjusted close was USD 7.18999. The average price that CGEM shares were previous bought at was USD 7.8634. The current market price is -8.6% lower than average price they were purchased at. The value of the holding in CGEM has fallen by USD 6,272 compared to the previous valuation of Cullinan Oncology LLC |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 39.68 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 39.68. The average price that CGON shares were previous bought at was USD 29.809. The current market price is 33.1% higher than average price they were purchased at. The value of the holding in CGON has fallen by USD 496 compared to the previous valuation of CG Oncology, Inc. Common stock |
| CNTA - Centessa Pharmaceuticals PLC ADR | HOLD | 0 @ USD 22.12 | USD 0 | The current share valuation price of CNTA based on adjusted close was USD 22.12. The average price that CNTA shares were previous bought at was USD 16.3476. The current market price is 35.3% higher than average price they were purchased at. The value of the holding in CNTA has fallen by USD 43,898 compared to the previous valuation of Centessa Pharmaceuticals PLC ADR |
| COGT - Cogent Biosciences Inc | HOLD | 0 @ USD 14.82 | USD 0 | The current share valuation price of COGT based on adjusted close was USD 14.82. The average price that COGT shares were previous bought at was USD 9.72589. The current market price is 52.4% higher than average price they were purchased at. The value of the holding in COGT has increased by USD 8,940 compared to the previous valuation of Cogent Biosciences Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| COLL - Collegium Pharmaceutical Inc | HOLD | 0 @ USD 42.3 | USD 0 | The current share valuation price of COLL based on adjusted close was USD 42.3. The average price that COLL shares were previous bought at was USD 31.389. The current market price is 34.8% higher than average price they were purchased at. The value of the holding in COLL has increased by USD 33,080 compared to the previous valuation of Collegium Pharmaceutical Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| CRNX - Crinetics Pharmaceuticals Inc | HOLD | 0 @ USD 40 | USD 0 | The current share valuation price of CRNX based on adjusted close was USD 40. The average price that CRNX shares were previous bought at was USD 34.9142. The current market price is 14.6% higher than average price they were purchased at. The value of the holding in CRNX has fallen by USD 212,998 compared to the previous valuation of Crinetics Pharmaceuticals Inc |
| CRSP - Crispr Therapeutics AG | HOLD | 0 @ USD 55.12 | USD 0 | The current share valuation price of CRSP based on adjusted close was USD 55.12. The average price that CRSP shares were previous bought at was USD 52.3425. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in CRSP has fallen by USD 87,399 compared to the previous valuation of Crispr Therapeutics AG |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 33.04 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 33.04. The average price that CSTL shares were previous bought at was USD 21.5031. The current market price is 53.7% higher than average price they were purchased at. The value of the holding in CSTL has fallen by USD 9,507 compared to the previous valuation of Castle Biosciences Inc |
| CVAC - CureVac NV | HOLD | 0 @ USD 5.21 | USD 0 | The current share valuation price of CVAC based on adjusted close was USD 5.21. The average price that CVAC shares were previous bought at was USD 4.81432. The current market price is 8.2% higher than average price they were purchased at. The value of the holding in CVAC has fallen by USD 5,770 compared to the previous valuation of CureVac NV |
| CYTK - Cytokinetics Inc | HOLD | 0 @ USD 60.16 | USD 0 | The current share valuation price of CYTK based on adjusted close was USD 60.16. The average price that CYTK shares were previous bought at was USD 42.4275. The current market price is 41.8% higher than average price they were purchased at. The value of the holding in CYTK has fallen by USD 10,804 compared to the previous valuation of Cytokinetics Inc |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 9.73 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 9.73. The average price that DAWN shares were previous bought at was USD 7.39484. The current market price is 31.6% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 48,192 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| DNLI - Denali Therapeutics Inc | HOLD | 0 @ USD 15.02 | USD 0 | The current share valuation price of DNLI based on adjusted close was USD 15.02. The average price that DNLI shares were previous bought at was USD 15.1282. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in DNLI has increased by USD 57,092 compared to the previous valuation of Denali Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 10.83 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 10.83. The average price that DVAX shares were previous bought at was USD 10.422. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in DVAX has fallen by USD 12,021 compared to the previous valuation of Dynavax Technologies Corporation |
| DYN - Dyne Therapeutics Inc | HOLD | 0 @ USD 18.36 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 18.36. The average price that DYN shares were previous bought at was USD 12.6915. The current market price is 44.7% higher than average price they were purchased at. The value of the holding in DYN has increased by USD 14,345 compared to the previous valuation of Dyne Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | HOLD | 0 @ USD 18.36 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 18.36. The average price that DYN shares were previous bought at was USD 12.6915. The current market price is 44.7% higher than average price they were purchased at. The value of the holding in DYN has increased by USD 14,345 compared to the previous valuation of DYNAGREEN EN.PR.GR.H YC 1 however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| EDIT - Editas Medicine Inc | HOLD | 0 @ USD 2.47 | USD 0 | The current share valuation price of EDIT based on adjusted close was USD 2.47. The average price that EDIT shares were previous bought at was USD 2.74932. The current market price is -10.2% lower than average price they were purchased at. The value of the holding in EDIT has fallen by USD 13,526 compared to the previous valuation of Editas Medicine Inc |
| ELVN - Enliven Therapeutics Inc. | HOLD | 0 @ USD 17.63 | USD 0 | The current share valuation price of ELVN based on adjusted close was USD 17.63. The average price that ELVN shares were previous bought at was USD 20.8303. The current market price is -15.4% lower than average price they were purchased at. The value of the holding in ELVN has fallen by USD 25,397 compared to the previous valuation of Enliven Therapeutics Inc. |
| EOLS - Evolus Inc | HOLD | 0 @ USD 6.55999 | USD 0 | The current share valuation price of EOLS based on adjusted close was USD 6.55999. The average price that EOLS shares were previous bought at was USD 9.2447. The current market price is -29.0% lower than average price they were purchased at. The value of the holding in EOLS has fallen by USD 27,852 compared to the previous valuation of Evolus Inc |
| ERAS - Erasca Inc | HOLD | 0 @ USD 2.27 | USD 0 | The current share valuation price of ERAS based on adjusted close was USD 2.27. The average price that ERAS shares were previous bought at was USD 1.63607. The current market price is 38.7% higher than average price they were purchased at. The value of the holding in ERAS has increased by USD 5,831 compared to the previous valuation of Erasca Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| EWTX - Edgewise Therapeutics Inc | HOLD | 0 @ USD 17.16 | USD 0 | The current share valuation price of EWTX based on adjusted close was USD 17.16. The average price that EWTX shares were previous bought at was USD 15.827. The current market price is 8.4% higher than average price they were purchased at. The value of the holding in EWTX has increased by USD 4,721 compared to the previous valuation of Edgewise Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 40.81 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 40.81. The average price that EXEL shares were previous bought at was USD 40.939. The current market price is -0.3% lower than average price they were purchased at. The value of the holding in EXEL has increased by USD 1,736 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| EYPT - Eyepoint Pharmaceuticals Inc | HOLD | 0 @ USD 11.21 | USD 0 | The current share valuation price of EYPT based on adjusted close was USD 11.21. The average price that EYPT shares were previous bought at was USD 8.67824. The current market price is 29.2% higher than average price they were purchased at. The value of the holding in EYPT has increased by USD 5,741 compared to the previous valuation of Eyepoint Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| FATE - Fate Therapeutics Inc | HOLD | 0 @ USD 1.07 | USD 0 | The current share valuation price of FATE based on adjusted close was USD 1.07. The average price that FATE shares were previous bought at was USD 1.19552. The current market price is -10.5% lower than average price they were purchased at. The value of the holding in FATE has increased by USD 2,094 compared to the previous valuation of Fate Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 10.5 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 10.5. The average price that FDMT shares were previous bought at was USD 6.22508. The current market price is 68.7% higher than average price they were purchased at. The value of the holding in FDMT has fallen by USD 13,469 compared to the previous valuation of 4D Molecular Therapeutics Inc |
| FOLD - Amicus Therapeutics Inc | HOLD | 0 @ USD 8.87 | USD 0 | The current share valuation price of FOLD based on adjusted close was USD 8.87. The average price that FOLD shares were previous bought at was USD 7.33773. The current market price is 20.9% higher than average price they were purchased at. The value of the holding in FOLD has fallen by USD 5,919 compared to the previous valuation of Amicus Therapeutics Inc |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 11.25 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 11.25. The average price that FTRE shares were previous bought at was USD 6.60705. The current market price is 70.3% higher than average price they were purchased at. The value of the holding in FTRE has increased by USD 13,383 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| GERN - Geron Corporation | HOLD | 0 @ USD 1.07 | USD 0 | The current share valuation price of GERN based on adjusted close was USD 1.07. The average price that GERN shares were previous bought at was USD 1.52831. The current market price is -30.0% lower than average price they were purchased at. The value of the holding in GERN has fallen by USD 4,047 compared to the previous valuation of Geron Corporation |
| GH - Guardant Health Inc | HOLD | 0 @ USD 96.72 | USD 0 | The current share valuation price of GH based on adjusted close was USD 96.72. The average price that GH shares were previous bought at was USD 54.3663. The current market price is 77.9% higher than average price they were purchased at. The value of the holding in GH has increased by USD 38,047 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 118.84 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 118.84. The average price that GILD shares were previous bought at was USD 112.041. The current market price is 6.1% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 2,159,329 compared to the previous valuation of Guild Esports Plc |
| GLPG - Galapagos NV ADR | HOLD | 0 @ USD 31.53 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 31.53. The average price that GLPG shares were previous bought at was USD 28.9971. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 3,203 compared to the previous valuation of Galapagos NV ADR however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| GLPG - Galapagos N.V. | HOLD | 0 @ USD 31.53 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 31.53. The average price that GLPG shares were previous bought at was USD 28.9971. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 3,203 compared to the previous valuation of Galapagos N.V. however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| GMAB - Genmab AS | HOLD | 0 @ USD 28.66 | USD 0 | The current share valuation price of GMAB based on adjusted close was USD 28.66. The average price that GMAB shares were previous bought at was USD 23.3088. The current market price is 23.0% higher than average price they were purchased at. The value of the holding in GMAB has fallen by USD 4,832 compared to the previous valuation of Genmab AS |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | HOLD | 0 @ USD 32.84 | USD 0 | The current share valuation price of GPCR based on adjusted close was USD 32.84. The average price that GPCR shares were previous bought at was USD 22.942. The current market price is 43.1% higher than average price they were purchased at. The value of the holding in GPCR has fallen by USD 24,027 compared to the previous valuation of Structure Therapeutics Inc. American Depositary Shares |
| GRAL - GRAIL, LLC | HOLD | 0 @ USD 79.4 | USD 0 | The current share valuation price of GRAL based on adjusted close was USD 79.4. The average price that GRAL shares were previous bought at was USD 52.1574. The current market price is 52.2% higher than average price they were purchased at. The value of the holding in GRAL has fallen by USD 15,503 compared to the previous valuation of GRAIL, LLC |
| GRFS - Grifols SA ADR | HOLD | 0 @ USD 8.44001 | USD 0 | The current share valuation price of GRFS based on adjusted close was USD 8.44001. The average price that GRFS shares were previous bought at was USD 9.40813. The current market price is -10.3% lower than average price they were purchased at. The value of the holding in GRFS has increased by USD 6,254 compared to the previous valuation of Grifols SA ADR however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 68.24 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 68.24. The average price that HALO shares were previous bought at was USD 59.5675. The current market price is 14.6% higher than average price they were purchased at. The value of the holding in HALO has fallen by USD 11,315 compared to the previous valuation of Halozyme Therapeutics Inc |
| HCM - HUTCHMED China Ltd | HOLD | 0 @ USD 14.95 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 14.95. The average price that HCM shares were previous bought at was USD 15.4366. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in HCM has fallen by USD 10,195 compared to the previous valuation of HUTCHMED China Ltd |
| HCM - Hitachi Construction Machinery Co. Ltd | HOLD | 0 @ USD 14.95 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 14.95. The average price that HCM shares were previous bought at was USD 15.4366. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in HCM has fallen by USD 10,195 compared to the previous valuation of Hitachi Construction Machinery Co. Ltd |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 31.43 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 31.43. The average price that HRMY shares were previous bought at was USD 31.7344. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in HRMY has increased by USD 18,047 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| HROW - Harrow Health Inc | HOLD | 0 @ USD 33.93 | USD 0 | The current share valuation price of HROW based on adjusted close was USD 33.93. The average price that HROW shares were previous bought at was USD 33.2683. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in HROW has fallen by USD 12,075 compared to the previous valuation of Harrow Health Inc |
| HUMA - Humacyte Inc | HOLD | 0 @ USD 1.33 | USD 0 | The current share valuation price of HUMA based on adjusted close was USD 1.33. The average price that HUMA shares were previous bought at was USD 2.22786. The current market price is -40.3% lower than average price they were purchased at. The value of the holding in HUMA has increased by USD 2,085 compared to the previous valuation of Humacyte Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.13 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.13. The average price that IBRX shares were previous bought at was USD 2.77166. The current market price is -23.2% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 6,138 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 30.24 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 30.24. The average price that IDYA shares were previous bought at was USD 23.1332. The current market price is 30.7% higher than average price they were purchased at. The value of the holding in IDYA has increased by USD 22,327 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 121.9 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 121.9. The average price that ILMN shares were previous bought at was USD 96.3187. The current market price is 26.6% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 78,312 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| IMCR - Immunocore Holdings Ltd | HOLD | 0 @ USD 33.5 | USD 0 | The current share valuation price of IMCR based on adjusted close was USD 33.5. The average price that IMCR shares were previous bought at was USD 32.6169. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in IMCR has increased by USD 50,182 compared to the previous valuation of Immunocore Holdings Ltd however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| IMVT - Immunovant Inc | HOLD | 0 @ USD 23.35 | USD 0 | The current share valuation price of IMVT based on adjusted close was USD 23.35. The average price that IMVT shares were previous bought at was USD 17.9316. The current market price is 30.2% higher than average price they were purchased at. The value of the holding in IMVT has fallen by USD 36,362 compared to the previous valuation of Immunovant Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 105.98 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 105.98. The average price that INCY shares were previous bought at was USD 73.2088. The current market price is 44.8% higher than average price they were purchased at. The value of the holding in INCY has increased by USD 98,551 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 189.7 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 189.7. The average price that INSM shares were previous bought at was USD 113.845. The current market price is 66.6% higher than average price they were purchased at. The value of the holding in INSM has increased by USD 549,293 compared to the previous valuation of Insmed Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| INVA - Innoviva Inc | HOLD | 0 @ USD 20.86 | USD 0 | The current share valuation price of INVA based on adjusted close was USD 20.86. The average price that INVA shares were previous bought at was USD 18.8748. The current market price is 10.5% higher than average price they were purchased at. The value of the holding in INVA has increased by USD 11,236 compared to the previous valuation of Innoviva Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| IONS - Ionis Pharmaceuticals Inc | HOLD | 0 @ USD 73.55 | USD 0 | The current share valuation price of IONS based on adjusted close was USD 73.55. The average price that IONS shares were previous bought at was USD 47.7228. The current market price is 54.1% higher than average price they were purchased at. The value of the holding in IONS has fallen by USD 56,820 compared to the previous valuation of Ionis Pharmaceuticals Inc |
| IRON - Ironveld Plc | HOLD | 0 @ USD 83.85 | USD 0 | The current share valuation price of IRON based on adjusted close was USD 83.85. The average price that IRON shares were previous bought at was USD 58.4084. The current market price is 43.6% higher than average price they were purchased at. The value of the holding in IRON has fallen by USD 71,360 compared to the previous valuation of Ironveld Plc |
| IRWD - Ironwood Pharmaceuticals Inc | HOLD | 0 @ USD 1.92 | USD 0 | The current share valuation price of IRWD based on adjusted close was USD 1.92. The average price that IRWD shares were previous bought at was USD 1.13295. The current market price is 69.5% higher than average price they were purchased at. The value of the holding in IRWD has fallen by USD 12,730 compared to the previous valuation of Ironwood Pharmaceuticals Inc |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 26.48 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 26.48. The average price that JANX shares were previous bought at was USD 27.7163. The current market price is -4.5% lower than average price they were purchased at. The value of the holding in JANX has fallen by USD 83,869 compared to the previous valuation of Janux Therapeutics Inc |
| JAZZ - Jazz Pharmaceuticals PLC | HOLD | 0 @ USD 131.16 | USD 0 | The current share valuation price of JAZZ based on adjusted close was USD 131.16. The average price that JAZZ shares were previous bought at was USD 121.521. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in JAZZ has fallen by USD 113,065 compared to the previous valuation of Jazz Pharmaceuticals PLC |
| KALV - Kalvista Pharmaceuticals Inc | HOLD | 0 @ USD 10.78 | USD 0 | The current share valuation price of KALV based on adjusted close was USD 10.78. The average price that KALV shares were previous bought at was USD 12.2548. The current market price is -12.0% lower than average price they were purchased at. The value of the holding in KALV has fallen by USD 3,462 compared to the previous valuation of Kalvista Pharmaceuticals Inc |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 38.37 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 38.37. The average price that KNSA shares were previous bought at was USD 29.5811. The current market price is 29.7% higher than average price they were purchased at. The value of the holding in KNSA has fallen by USD 7,339 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd |
| KROS - Keros Therapeutics Inc | HOLD | 0 @ USD 16.2 | USD 0 | The current share valuation price of KROS based on adjusted close was USD 16.2. The average price that KROS shares were previous bought at was USD 13.6498. The current market price is 18.7% higher than average price they were purchased at. The value of the holding in KROS has increased by USD 768 compared to the previous valuation of Keros Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| KRYS - Krystal Biotech Inc | HOLD | 0 @ USD 197.93 | USD 0 | The current share valuation price of KRYS based on adjusted close was USD 197.93. The average price that KRYS shares were previous bought at was USD 159.904. The current market price is 23.8% higher than average price they were purchased at. The value of the holding in KRYS has fallen by USD 38,167 compared to the previous valuation of Krystal Biotech Inc |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 9.86001 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 9.86001. The average price that KURA shares were previous bought at was USD 7.21533. The current market price is 36.7% higher than average price they were purchased at. The value of the holding in KURA has fallen by USD 17,383 compared to the previous valuation of Kura Oncology Inc |
| KYMR - Kymera Therapeutics Inc | HOLD | 0 @ USD 58.66 | USD 0 | The current share valuation price of KYMR based on adjusted close was USD 58.66. The average price that KYMR shares were previous bought at was USD 45.7331. The current market price is 28.3% higher than average price they were purchased at. The value of the holding in KYMR has fallen by USD 108,499 compared to the previous valuation of Kymera Therapeutics Inc |
| LEGN - Legend Biotech Corp | HOLD | 0 @ USD 31.8 | USD 0 | The current share valuation price of LEGN based on adjusted close was USD 31.8. The average price that LEGN shares were previous bought at was USD 34.6859. The current market price is -8.3% lower than average price they were purchased at. The value of the holding in LEGN has fallen by USD 30,991 compared to the previous valuation of Legend Biotech Corp |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 202.48 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 202.48. The average price that LGND shares were previous bought at was USD 131.708. The current market price is 53.7% higher than average price they were purchased at. The value of the holding in LGND has fallen by USD 73,059 compared to the previous valuation of Ligand Pharmaceuticals Incorporated |
| LXRX - Lexicon Pharmaceuticals Inc | HOLD | 0 @ USD 1.25 | USD 0 | The current share valuation price of LXRX based on adjusted close was USD 1.25. The average price that LXRX shares were previous bought at was USD 1.03946. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in LXRX has fallen by USD 43,574 compared to the previous valuation of Lexicon Pharmaceuticals Inc |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 17.51 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 17.51. The average price that LYEL shares were previous bought at was USD 3.96367. The current market price is 341.8% higher than average price they were purchased at. The value of the holding in LYEL has fallen by USD 4,559 compared to the previous valuation of Lyell Immunopharma Inc |
| MDGL - Madrigal Pharmaceuticals Inc | HOLD | 0 @ USD 489.26 | USD 0 | The current share valuation price of MDGL based on adjusted close was USD 489.26. The average price that MDGL shares were previous bought at was USD 344.622. The current market price is 42.0% higher than average price they were purchased at. The value of the holding in MDGL has increased by USD 9,776 compared to the previous valuation of Madrigal Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 589.15 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 589.15. The average price that MEDP shares were previous bought at was USD 387.722. The current market price is 52.0% higher than average price they were purchased at. The value of the holding in MEDP has fallen by USD 55,267 compared to the previous valuation of Medpace Holdings Inc |
| MGNX - MacroGenics Inc | HOLD | 0 @ USD 1.37001 | USD 0 | The current share valuation price of MGNX based on adjusted close was USD 1.37001. The average price that MGNX shares were previous bought at was USD 1.58167. The current market price is -13.4% lower than average price they were purchased at. The value of the holding in MGNX has increased by USD 396 compared to the previous valuation of MacroGenics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| MGTX - MeiraGTx Holdings PLC | HOLD | 0 @ USD 8.47 | USD 0 | The current share valuation price of MGTX based on adjusted close was USD 8.47. The average price that MGTX shares were previous bought at was USD 7.16643. The current market price is 18.2% higher than average price they were purchased at. The value of the holding in MGTX has increased by USD 3,094 compared to the previous valuation of MeiraGTx Holdings PLC however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| MIRM - Mirum Pharmaceuticals Inc | HOLD | 0 @ USD 68.11 | USD 0 | The current share valuation price of MIRM based on adjusted close was USD 68.11. The average price that MIRM shares were previous bought at was USD 55.2082. The current market price is 23.4% higher than average price they were purchased at. The value of the holding in MIRM has increased by USD 12,728 compared to the previous valuation of Mirum Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 38.02 | USD 0 | The current share valuation price of MLYS based on adjusted close was USD 38.02. The average price that MLYS shares were previous bought at was USD 19.4249. The current market price is 95.7% higher than average price they were purchased at. The value of the holding in MLYS has increased by USD 42,836 compared to the previous valuation of Mineralys Therapeutics, Inc. Common Stock however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| MNKD - MannKind Corp | HOLD | 0 @ USD 5.63 | USD 0 | The current share valuation price of MNKD based on adjusted close was USD 5.63. The average price that MNKD shares were previous bought at was USD 4.73822. The current market price is 18.8% higher than average price they were purchased at. The value of the holding in MNKD has fallen by USD 13,758 compared to the previous valuation of MannKind Corp |
| MNMD - Mind Medicine Inc | HOLD | 0 @ USD 11.7 | USD 0 | The current share valuation price of MNMD based on adjusted close was USD 11.7. The average price that MNMD shares were previous bought at was USD 8.50403. The current market price is 37.6% higher than average price they were purchased at. The value of the holding in MNMD has increased by USD 17,874 compared to the previous valuation of Mind Medicine Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 24.54 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 24.54. The average price that MRNA shares were previous bought at was USD 29.1568. The current market price is -15.8% lower than average price they were purchased at. The value of the holding in MRNA has increased by USD 52,698 compared to the previous valuation of Moderna Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| MRSN - Mersana Therapeutics Inc | HOLD | 0 @ USD 8.41005 | USD 0 | The current share valuation price of MRSN based on adjusted close was USD 8.41005. The average price that MRSN shares were previous bought at was USD 0.522006. The current market price is 1,511.1% higher than average price they were purchased at. The value of the holding in MRSN has increased by USD 1,119 compared to the previous valuation of Mersana Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 95.23 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 95.23. The average price that MRUS shares were previous bought at was USD 62.909. The current market price is 51.4% higher than average price they were purchased at. The value of the holding in MRUS has increased by USD 3,423 compared to the previous valuation of Merus BV however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 2.87 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 2.87. The average price that MRVI shares were previous bought at was USD 2.69314. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in MRVI has fallen by USD 2,002 compared to the previous valuation of Maravai Lifesciences Holdings Inc |
| MXCT - MaxCyte Inc | HOLD | 0 @ USD 1.44 | USD 0 | The current share valuation price of MXCT based on adjusted close was USD 1.44. The average price that MXCT shares were previous bought at was USD 2.19832. The current market price is -34.5% lower than average price they were purchased at. The value of the holding in MXCT has fallen by USD 2,057 compared to the previous valuation of MaxCyte Inc |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 152.37 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 152.37. The average price that NBIX shares were previous bought at was USD 129.232. The current market price is 17.9% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 156,049 compared to the previous valuation of Neurocrine Biosciences Inc |
| NRIX - Nurix Therapeutics Inc | HOLD | 0 @ USD 12.31 | USD 0 | The current share valuation price of NRIX based on adjusted close was USD 12.31. The average price that NRIX shares were previous bought at was USD 12.0458. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in NRIX has fallen by USD 10,814 compared to the previous valuation of Nurix Therapeutics Inc |
| NTLA - Intellia Therapeutics Inc | HOLD | 0 @ USD 9.52 | USD 0 | The current share valuation price of NTLA based on adjusted close was USD 9.52. The average price that NTLA shares were previous bought at was USD 12.5091. The current market price is -23.9% lower than average price they were purchased at. The value of the holding in NTLA has fallen by USD 194,874 compared to the previous valuation of Intellia Therapeutics Inc |
| NUVL - Nuvalent Inc | HOLD | 0 @ USD 93.35 | USD 0 | The current share valuation price of NUVL based on adjusted close was USD 93.35. The average price that NUVL shares were previous bought at was USD 81.7397. The current market price is 14.2% higher than average price they were purchased at. The value of the holding in NUVL has fallen by USD 108,499 compared to the previous valuation of Nuvalent Inc |
| NVAX - Novavax Inc | HOLD | 0 @ USD 7.44 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.44. The average price that NVAX shares were previous bought at was USD 7.41065. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 15,606 compared to the previous valuation of Novavax Inc |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 7.44 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.44. The average price that NVAX shares were previous bought at was USD 7.41065. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 15,606 compared to the previous valuation of Hana Microelectronics Public Company Limited |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 10.92 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 10.92. The average price that NVCR shares were previous bought at was USD 16.9001. The current market price is -35.4% lower than average price they were purchased at. The value of the holding in NVCR has fallen by USD 25,060 compared to the previous valuation of Novocure Ltd |
| OABI - OmniAb Inc. | HOLD | 0 @ USD 1.38 | USD 0 | The current share valuation price of OABI based on adjusted close was USD 1.38. The average price that OABI shares were previous bought at was USD 1.92012. The current market price is -28.1% lower than average price they were purchased at. USD 0 compared to the previous valuation of OmniAb Inc. |
| OCUL - Ocular Therapeutix Inc | HOLD | 0 @ USD 10.85 | USD 0 | The current share valuation price of OCUL based on adjusted close was USD 10.85. The average price that OCUL shares were previous bought at was USD 9.60211. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in OCUL has increased by USD 24,501 compared to the previous valuation of Ocular Therapeutix Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| OKUR - OKUR | HOLD | 0 @ USD 2.94002 | USD 0 | The current share valuation price of OKUR based on adjusted close was USD 2.94002. The average price that OKUR shares were previous bought at was USD 6.18362. The current market price is -52.5% lower than average price they were purchased at. The value of the holding in OKUR has fallen by USD 1,713 compared to the previous valuation of OKUR |
| OLMA - Olema Pharmaceuticals Inc | HOLD | 0 @ USD 8.35 | USD 0 | The current share valuation price of OLMA based on adjusted close was USD 8.35. The average price that OLMA shares were previous bought at was USD 5.49797. The current market price is 51.9% higher than average price they were purchased at. The value of the holding in OLMA has increased by USD 6,908 compared to the previous valuation of Olema Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ORIC - Oric Pharmaceuticals Inc | HOLD | 0 @ USD 12.35 | USD 0 | The current share valuation price of ORIC based on adjusted close was USD 12.35. The average price that ORIC shares were previous bought at was USD 10.4607. The current market price is 18.1% higher than average price they were purchased at. The value of the holding in ORIC has fallen by USD 12,433 compared to the previous valuation of Oric Pharmaceuticals Inc |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.76 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.76. The average price that PACB shares were previous bought at was USD 1.54587. The current market price is 13.9% higher than average price they were purchased at. The value of the holding in PACB has fallen by USD 4,060 compared to the previous valuation of Pacific Biosciences of California |
| PAHC - Phibro Animal Health Corporation | HOLD | 0 @ USD 43.76 | USD 0 | The current share valuation price of PAHC based on adjusted close was USD 43.76. The average price that PAHC shares were previous bought at was USD 28.2645. The current market price is 54.8% higher than average price they were purchased at. The value of the holding in PAHC has increased by USD 9,280 compared to the previous valuation of Phibro Animal Health Corporation however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| PCRX - Pacira BioSciences, Inc. | HOLD | 0 @ USD 22.05 | USD 0 | The current share valuation price of PCRX based on adjusted close was USD 22.05. The average price that PCRX shares were previous bought at was USD 23.8493. The current market price is -7.5% lower than average price they were purchased at. The value of the holding in PCRX has increased by USD 27,330 compared to the previous valuation of Pacira BioSciences, Inc. however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| PCVX - Vaxcyte Inc | HOLD | 0 @ USD 41.65 | USD 0 | The current share valuation price of PCVX based on adjusted close was USD 41.65. The average price that PCVX shares were previous bought at was USD 44.7265. The current market price is -6.9% lower than average price they were purchased at. The value of the holding in PCVX has fallen by USD 5,035 compared to the previous valuation of Vaxcyte Inc |
| PGEN - Precigen Inc | HOLD | 0 @ USD 3.9 | USD 0 | The current share valuation price of PGEN based on adjusted close was USD 3.9. The average price that PGEN shares were previous bought at was USD 2.24578. The current market price is 73.7% higher than average price they were purchased at. The value of the holding in PGEN has fallen by USD 3,905 compared to the previous valuation of Precigen Inc |
| PHAT - Phathom Pharmaceuticals Inc | HOLD | 0 @ USD 13.25 | USD 0 | The current share valuation price of PHAT based on adjusted close was USD 13.25. The average price that PHAT shares were previous bought at was USD 8.87379. The current market price is 49.3% higher than average price they were purchased at. The value of the holding in PHAT has increased by USD 9,736 compared to the previous valuation of Phathom Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| PLRX - Pliant Therapeutics Inc | HOLD | 0 @ USD 1.59999 | USD 0 | The current share valuation price of PLRX based on adjusted close was USD 1.59999. The average price that PLRX shares were previous bought at was USD 1.49619. The current market price is 6.9% higher than average price they were purchased at. The value of the holding in PLRX has increased by USD 2,611 compared to the previous valuation of Pliant Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 168.22 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 168.22. The average price that PRAX shares were previous bought at was USD 60.0993. The current market price is 179.9% higher than average price they were purchased at. The value of the holding in PRAX has fallen by USD 56,305 compared to the previous valuation of Praxis Precision Medicines Inc |
| PRME - Prime Medicine, Inc. Common Stock | HOLD | 0 @ USD 3.81 | USD 0 | The current share valuation price of PRME based on adjusted close was USD 3.81. The average price that PRME shares were previous bought at was USD 3.97738. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in PRME has fallen by USD 41,434 compared to the previous valuation of Prime Medicine, Inc. Common Stock |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 10.56 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 10.56. The average price that PRTA shares were previous bought at was USD 9.02717. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in PRTA has increased by USD 16,895 compared to the previous valuation of Prothena Corporation plc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 71.78 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 71.78. The average price that PTCT shares were previous bought at was USD 54.5161. The current market price is 31.7% higher than average price they were purchased at. The value of the holding in PTCT has fallen by USD 41,601 compared to the previous valuation of PTC Therapeutics Inc |
| PTGX - Protagonist Therapeutics Inc | HOLD | 0 @ USD 79.54 | USD 0 | The current share valuation price of PTGX based on adjusted close was USD 79.54. The average price that PTGX shares were previous bought at was USD 56.0396. The current market price is 41.9% higher than average price they were purchased at. The value of the holding in PTGX has fallen by USD 9,678 compared to the previous valuation of Protagonist Therapeutics Inc |
| QURE - Uniqure NV | HOLD | 0 @ USD 27.79 | USD 0 | The current share valuation price of QURE based on adjusted close was USD 27.79. The average price that QURE shares were previous bought at was USD 23.0704. The current market price is 20.5% higher than average price they were purchased at. The value of the holding in QURE has increased by USD 9,909 compared to the previous valuation of Uniqure NV however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| RARE - Ultragenyx | HOLD | 0 @ USD 30.63 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 30.63. The average price that RARE shares were previous bought at was USD 36.5596. The current market price is -16.2% lower than average price they were purchased at. The value of the holding in RARE has fallen by USD 20,101 compared to the previous valuation of Ultragenyx |
| RARE - WISETFWTMRARETFP | HOLD | 0 @ USD 30.63 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 30.63. The average price that RARE shares were previous bought at was USD 36.5596. The current market price is -16.2% lower than average price they were purchased at. The value of the holding in RARE has fallen by USD 20,101 compared to the previous valuation of WISETFWTMRARETFP |
| RCKT - Rocket Pharmaceuticals Inc | HOLD | 0 @ USD 3.16999 | USD 0 | The current share valuation price of RCKT based on adjusted close was USD 3.16999. The average price that RCKT shares were previous bought at was USD 5.21303. The current market price is -39.2% lower than average price they were purchased at. The value of the holding in RCKT has fallen by USD 4,108 compared to the previous valuation of Rocket Pharmaceuticals Inc |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 657.53 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 657.53. The average price that REGN shares were previous bought at was USD 627.339. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in REGN has increased by USD 711,949 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| REPL - Replimune Group Inc | HOLD | 0 @ USD 8.31 | USD 0 | The current share valuation price of REPL based on adjusted close was USD 8.31. The average price that REPL shares were previous bought at was USD 8.93706. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in REPL has fallen by USD 9,735 compared to the previous valuation of Replimune Group Inc |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 11.21 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 11.21. The average price that RGNX shares were previous bought at was USD 9.12904. The current market price is 22.8% higher than average price they were purchased at. The value of the holding in RGNX has increased by USD 1,346 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 6.05 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 6.05. The average price that RLAY shares were previous bought at was USD 4.12543. The current market price is 46.7% higher than average price they were purchased at. The value of the holding in RLAY has fallen by USD 53,046 compared to the previous valuation of Relay Therapeutics Inc |
| RNA - Avidity Biosciences Inc | HOLD | 0 @ USD 69.84 | USD 0 | The current share valuation price of RNA based on adjusted close was USD 69.84. The average price that RNA shares were previous bought at was USD 36.0992. The current market price is 93.5% higher than average price they were purchased at. The value of the holding in RNA has increased by USD 4,979 compared to the previous valuation of Avidity Biosciences Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| ROIV - Roivant Sciences Ltd | HOLD | 0 @ USD 20.62 | USD 0 | The current share valuation price of ROIV based on adjusted close was USD 20.62. The average price that ROIV shares were previous bought at was USD 12.7263. The current market price is 62.0% higher than average price they were purchased at. The value of the holding in ROIV has increased by USD 22,021 compared to the previous valuation of Roivant Sciences Ltd however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 38.56 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 38.56. The average price that RPRX shares were previous bought at was USD 35.4226. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in RPRX has fallen by USD 618,941 compared to the previous valuation of Royalty Pharma Plc |
| RVMD - Revolution Medicines Inc | HOLD | 0 @ USD 61.01 | USD 0 | The current share valuation price of RVMD based on adjusted close was USD 61.01. The average price that RVMD shares were previous bought at was USD 41.084. The current market price is 48.5% higher than average price they were purchased at. The value of the holding in RVMD has fallen by USD 44,846 compared to the previous valuation of Revolution Medicines Inc |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.62 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.62. The average price that RXRX shares were previous bought at was USD 5.7985. The current market price is -20.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Recursion Pharmaceuticals Inc |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 100.3 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 100.3. The average price that RYTM shares were previous bought at was USD 75.0955. The current market price is 33.6% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 77,953 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| SANA - Sana Biotechnology Inc | HOLD | 0 @ USD 4.09 | USD 0 | The current share valuation price of SANA based on adjusted close was USD 4.09. The average price that SANA shares were previous bought at was USD 3.14576. The current market price is 30.0% higher than average price they were purchased at. The value of the holding in SANA has increased by USD 6,732 compared to the previous valuation of Sana Biotechnology Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| SIGA - SIGA Technologies Inc | HOLD | 0 @ USD 6.54 | USD 0 | The current share valuation price of SIGA based on adjusted close was USD 6.54. The average price that SIGA shares were previous bought at was USD 6.82605. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in SIGA has fallen by USD 73,498 compared to the previous valuation of SIGA Technologies Inc |
| SMMT - Summit Therapeutics PLC | HOLD | 0 @ USD 18.18 | USD 0 | The current share valuation price of SMMT based on adjusted close was USD 18.18. The average price that SMMT shares were previous bought at was USD 21.3588. The current market price is -14.9% lower than average price they were purchased at. The value of the holding in SMMT has fallen by USD 129,870 compared to the previous valuation of Summit Therapeutics PLC |
| SNDX - Syndax Pharmaceuticals Inc | HOLD | 0 @ USD 15.04 | USD 0 | The current share valuation price of SNDX based on adjusted close was USD 15.04. The average price that SNDX shares were previous bought at was USD 11.5977. The current market price is 29.7% higher than average price they were purchased at. The value of the holding in SNDX has increased by USD 19,312 compared to the previous valuation of Syndax Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| SNY - Sanofi ADR | HOLD | 0 @ USD 49.66 | USD 0 | The current share valuation price of SNY based on adjusted close was USD 49.66. The average price that SNY shares were previous bought at was USD 50.0044. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in SNY has increased by USD 29,542 compared to the previous valuation of Sanofi ADR however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| SPRY - Silverback Therapeutics Inc | HOLD | 0 @ USD 8.85 | USD 0 | The current share valuation price of SPRY based on adjusted close was USD 8.85. The average price that SPRY shares were previous bought at was USD 13.7417. The current market price is -35.6% lower than average price they were purchased at. The value of the holding in SPRY has increased by USD 41,016 compared to the previous valuation of Silverback Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 17.63 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 17.63. The average price that SRPT shares were previous bought at was USD 34.6821. The current market price is -49.2% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 625 compared to the previous valuation of Sarepta Therapeutics Inc |
| SRRK - Scholar Rock Holding Corp | HOLD | 0 @ USD 28.95 | USD 0 | The current share valuation price of SRRK based on adjusted close was USD 28.95. The average price that SRRK shares were previous bought at was USD 34.959. The current market price is -17.2% lower than average price they were purchased at. The value of the holding in SRRK has increased by USD 9,355 compared to the previous valuation of Scholar Rock Holding Corp however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 22.86 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 22.86. The average price that STOK shares were previous bought at was USD 15.685. The current market price is 45.7% higher than average price they were purchased at. The value of the holding in STOK has increased by USD 13,966 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| STRO - Sutro Biopharma | HOLD | 0 @ USD 0.816292 | USD 0 | The current share valuation price of STRO based on adjusted close was USD 0.816292. The average price that STRO shares were previous bought at was USD 0.904658. The current market price is -9.8% lower than average price they were purchased at. The value of the holding in STRO has fallen by USD 6,365 compared to the previous valuation of Sutro Biopharma |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 46.02 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 46.02. The average price that SUPN shares were previous bought at was USD 37.4665. The current market price is 22.8% higher than average price they were purchased at. The value of the holding in SUPN has fallen by USD 45,573 compared to the previous valuation of Supernus Pharmaceuticals Inc |
| SVRA - Savara Inc | HOLD | 0 @ USD 3.95 | USD 0 | The current share valuation price of SVRA based on adjusted close was USD 3.95. The average price that SVRA shares were previous bought at was USD 2.77267. The current market price is 42.5% higher than average price they were purchased at. The value of the holding in SVRA has fallen by USD 3,307 compared to the previous valuation of Savara Inc |
| SYRE - Spyre Therapeutics Inc. | HOLD | 0 @ USD 22.52 | USD 0 | The current share valuation price of SYRE based on adjusted close was USD 22.52. The average price that SYRE shares were previous bought at was USD 17.3981. The current market price is 29.4% higher than average price they were purchased at. The value of the holding in SYRE has increased by USD 5,003 compared to the previous valuation of Spyre Therapeutics Inc. however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| TARS - Tarsus Pharmaceuticals Inc | HOLD | 0 @ USD 68.25 | USD 0 | The current share valuation price of TARS based on adjusted close was USD 68.25. The average price that TARS shares were previous bought at was USD 48.764. The current market price is 40.0% higher than average price they were purchased at. The value of the holding in TARS has increased by USD 4,401 compared to the previous valuation of Tarsus Pharmaceuticals Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| TBPH - Theravance Biopharma Inc | HOLD | 0 @ USD 14.75 | USD 0 | The current share valuation price of TBPH based on adjusted close was USD 14.75. The average price that TBPH shares were previous bought at was USD 11.6399. The current market price is 26.7% higher than average price they were purchased at. The value of the holding in TBPH has fallen by USD 3,873 compared to the previous valuation of Theravance Biopharma Inc |
| TERN - Tern Plc | HOLD | 0 @ USD 18.47 | USD 0 | The current share valuation price of TERN based on adjusted close was USD 18.47. The average price that TERN shares were previous bought at was USD 5.24813. The current market price is 251.9% higher than average price they were purchased at. The value of the holding in TERN has increased by USD 12,344 compared to the previous valuation of Tern Plc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| TNGX - Tango Therapeutics Inc | HOLD | 0 @ USD 7.87 | USD 0 | The current share valuation price of TNGX based on adjusted close was USD 7.87. The average price that TNGX shares were previous bought at was USD 6.1116. The current market price is 28.8% higher than average price they were purchased at. The value of the holding in TNGX has fallen by USD 9,971 compared to the previous valuation of Tango Therapeutics Inc |
| TRDA - Entrada Therapeutics Inc | HOLD | 0 @ USD 6.91002 | USD 0 | The current share valuation price of TRDA based on adjusted close was USD 6.91002. The average price that TRDA shares were previous bought at was USD 7.65435. The current market price is -9.7% lower than average price they were purchased at. The value of the holding in TRDA has fallen by USD 1,049 compared to the previous valuation of Entrada Therapeutics Inc |
| TSHA - Taysha Gene Therapies Inc | HOLD | 0 @ USD 3.83 | USD 0 | The current share valuation price of TSHA based on adjusted close was USD 3.83. The average price that TSHA shares were previous bought at was USD 2.85863. The current market price is 34.0% higher than average price they were purchased at. The value of the holding in TSHA has fallen by USD 15,735 compared to the previous valuation of Taysha Gene Therapies Inc |
| TVTX - Travere Therapeutics Inc | HOLD | 0 @ USD 32.34 | USD 0 | The current share valuation price of TVTX based on adjusted close was USD 32.34. The average price that TVTX shares were previous bought at was USD 19.5465. The current market price is 65.5% higher than average price they were purchased at. The value of the holding in TVTX has fallen by USD 54,768 compared to the previous valuation of Travere Therapeutics Inc |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 30.27 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 30.27. The average price that TWST shares were previous bought at was USD 36.4329. The current market price is -16.9% lower than average price they were purchased at. The value of the holding in TWST has fallen by USD 13,913 compared to the previous valuation of Twist Bioscience Corp |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 15.25 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 15.25. The average price that TXG shares were previous bought at was USD 11.9918. The current market price is 27.2% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 166,637 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 15.25 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 15.25. The average price that TXG shares were previous bought at was USD 11.9918. The current market price is 27.2% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 166,637 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 448.91 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 448.91. The average price that UTHR shares were previous bought at was USD 341.856. The current market price is 31.3% higher than average price they were purchased at. The value of the holding in UTHR has fallen by USD 148,923 compared to the previous valuation of United Therapeutics Corporation |
| VCEL - Vericel Corp Ord | HOLD | 0 @ USD 38.94 | USD 0 | The current share valuation price of VCEL based on adjusted close was USD 38.94. The average price that VCEL shares were previous bought at was USD 40.8333. The current market price is -4.6% lower than average price they were purchased at. The value of the holding in VCEL has increased by USD 6,138 compared to the previous valuation of Vericel Corp Ord however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 41.7 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 41.7. The average price that VCYT shares were previous bought at was USD 31.1381. The current market price is 33.9% higher than average price they were purchased at. The value of the holding in VCYT has increased by USD 514 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| VERA - Vera Therapeutics Inc | HOLD | 0 @ USD 24.19 | USD 0 | The current share valuation price of VERA based on adjusted close was USD 24.19. The average price that VERA shares were previous bought at was USD 26.9141. The current market price is -10.1% lower than average price they were purchased at. The value of the holding in VERA has fallen by USD 42,074 compared to the previous valuation of Vera Therapeutics Inc |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.13 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.13. The average price that VIR shares were previous bought at was USD 5.84572. The current market price is -12.2% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 884 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.13 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.13. The average price that VIR shares were previous bought at was USD 5.84572. The current market price is -12.2% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 884 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 4.4 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 4.4. The average price that VNDA shares were previous bought at was USD 4.85747. The current market price is -9.4% lower than average price they were purchased at. The value of the holding in VNDA has fallen by USD 410 compared to the previous valuation of Vanda Pharmaceuticals Inc |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 409.47 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 409.47. The average price that VRTX shares were previous bought at was USD 439.131. The current market price is -6.8% lower than average price they were purchased at. The value of the holding in VRTX has fallen by USD 927,572 compared to the previous valuation of Vertex Pharmaceuticals Inc |
| VTRS - Viatris Inc | HOLD | 0 @ USD 10.12 | USD 0 | The current share valuation price of VTRS based on adjusted close was USD 10.12. The average price that VTRS shares were previous bought at was USD 9.5689. The current market price is 5.8% higher than average price they were purchased at. The value of the holding in VTRS has increased by USD 7,555 compared to the previous valuation of Viatris Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| VYGR - Voyager Therapeutics Inc | HOLD | 0 @ USD 4.23 | USD 0 | The current share valuation price of VYGR based on adjusted close was USD 4.23. The average price that VYGR shares were previous bought at was USD 3.8543. The current market price is 9.7% higher than average price they were purchased at. The value of the holding in VYGR has increased by USD 330 compared to the previous valuation of Voyager Therapeutics Inc however if the holding was sold on 2025-11-07 this would crystalise an overall loss. |
| WVE - Wave Life Sciences Ltd | HOLD | 0 @ USD 7.86 | USD 0 | The current share valuation price of WVE based on adjusted close was USD 7.86. The average price that WVE shares were previous bought at was USD 8.46992. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in WVE has fallen by USD 2,089 compared to the previous valuation of Wave Life Sciences Ltd |
| XENE - Xenon Pharmaceuticals Inc | HOLD | 0 @ USD 38.25 | USD 0 | The current share valuation price of XENE based on adjusted close was USD 38.25. The average price that XENE shares were previous bought at was USD 35.5575. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in XENE has fallen by USD 2,511 compared to the previous valuation of Xenon Pharmaceuticals Inc |
| XNCR - Xencor Inc | HOLD | 0 @ USD 13.9 | USD 0 | The current share valuation price of XNCR based on adjusted close was USD 13.9. The average price that XNCR shares were previous bought at was USD 11.1418. The current market price is 24.8% higher than average price they were purchased at. The value of the holding in XNCR has fallen by USD 4,569 compared to the previous valuation of Xencor Inc |
| ZLAB - Zai Lab Ltd | HOLD | 0 @ USD 21.9 | USD 0 | The current share valuation price of ZLAB based on adjusted close was USD 21.9. The average price that ZLAB shares were previous bought at was USD 34.1121. The current market price is -35.8% lower than average price they were purchased at. The value of the holding in ZLAB has fallen by USD 38,277 compared to the previous valuation of Zai Lab Ltd |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 16.46 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 16.46. The average price that ZYME shares were previous bought at was USD 14.2548. The current market price is 15.5% higher than average price they were purchased at. The value of the holding in ZYME has fallen by USD 71,357 compared to the previous valuation of Zymeworks Inc. Common Stock |